The latest report by IMARC, titled “Vasomotor Symptoms Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2033“, the global vasomotor symptoms market size witnessing a steady growth. Vasomotor symptoms (VMS) are group symptoms caused by hormonal imbalance in women during the menopause or perimenopause phase. It includes hot flashes, palpitation, chills, night sweat, anxiety, and sleep disturbances. These symptoms are diagnosed through blood tests, pelvic exams, thyroid function tests, magnetic resonance imaging (MRI), and thermography. VMS can be treated using hormone therapy, non-hormonal medications, lifestyle changes, and various alternative therapies, such as acupuncture, hypnosis, and herbal supplements. These treatments aid in minimizing the severity and frequency of symptoms, improving sleep quality, preventing bone loss, and reducing the risk of depression, anxiety, osteoporosis, and cardiovascular diseases in women.
Global Vasomotor Symptoms Market Trends:
The increasing prevalence of vasomotor symptoms due to hormonal fluctuation, genetics, sedentary lifestyle, and unhealthy eating habits are among the key factors driving the market growth. In addition to this, the growing demand for safe, effective, and convenient VMS treatment options attributed to the rising geriatric population is favoring the market growth.. Furthermore, increasing government initiatives and favorable policies to educate the masses, spread awareness, and support the development and commercialization of VMS treatments is providing an impetus to the market growth. Additionally, the recent development of transdermal estrogen therapy that delivers estrogen through a patch on the skin, which, in turn, improves drug absorption, enhances efficacy, and reduces the risk of blood clots and strokes, is creating a positive outlook for the market. Besides this, the introduction of non-invasive treatments, such as laser therapy, which utilizes low-intensity lasers to stimulate acupuncture points associated with VMS symptoms, is acting as another growth-inducing factor. Moreover, increasing demand for natural and herbal treatments that are safe, cost-effective, and reduce the severity of hot flashes and other symptoms is propelling the market growth. Other factors, including rising awareness regarding women's health, significant growth in the healthcare industry, increasing investment in the research and development (R&D) of advanced therapeutics, and the introduction of mobile applications to manage and record VMS, are anticipated to drive the market growth.
- Region-wise, the market has been classified into the United States, EU5 (Germany, France, the United Kingdom, Italy, and Spain), and Japan. The United States has the largest patient population for vasomotor symptoms and also represents the largest market for its treatment among the seven major markets.
- This research study also offers a thorough overview of late-stage pipeline candidates and currently marketed medications for vasomotor symptoms.
- The study also offers a thorough overview of the treatment practices for vasomotor symptoms, the share of specific therapies, and the performance of key market players.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800